Month: January 2025

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB StudySession...

MONTREAL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that its wholly owned subsidiary Canadian Health Care Agency Ltd (CHCA) was retained as service provider to provide travel nurse contingent labour services to the Nova Scotia Health Authority (NSHA). The agreement has a duration of 3 years, positions CHCA as a vendor of reference with NSHA, and covers Registered Nurses, Specialty Registered Nurses and Licensed Practical Nurses roles. The agreement, as most independent labor contract awards are, is for an execution on request contract which purpose is to meet recurring personnel needs, but for which the number, pace, or frequency of service requests are uncertain. “We are pleased to have the opportunity to...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Highlights will include overviews of Calidi’s lead programs, such as its CLD-400 systemic platform targeting metastatic cancers, CLD-201 for advanced solid tumors and CLD-101 for high-grade glioma. A live Q&A session with the leadership...

SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of...

Three Consecutive Years Without Lost-time Accidents VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce that Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile, has reached a significant safety milestone, marked by three consecutive years without lost-time accidents. During these three years, a total of 1,823,782 man-hours were lodged by MVC’s employees. “This new safety record reached by the MVC team is significant as it demonstrates the safety mindset and the effectiveness of the safety practices, training programs and tools in place at our operation. Our maxims that safety supersedes all production goals and that all workers should return home unharmed each day have clearly...

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:  Conference: Guggenheim SMID Cap Biotech Conference       Date/Time: Wednesday, February 5, 2025, at 9:30 a.m. EST     The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow...

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:30 p.m. ET in New York, NY. A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences...

The first Head of State multi-mission Global 7500 aircraft delivered to armasuisse by Bombardier Defense was unveiled to the public on January 29th, in Bern, Switzerland Military and government operators appreciate the Global 7500 aircraft’s capabilities that optimize performance, efficiency and safety to support both head-of-state transportation and emergency evacuation missions Bombardier Defense has an active fleet of Global and Challenger aircraft in service that are tailored to ensure maximized efficiency for government transport, by gearing the cabin for productivity and safetyBERN, Switzerland, Jan. 29, 2025 (GLOBE NEWSWIRE) — Bombardier Defense today celebrated the first public unveiling of armasuisse’s newly-delivered Global 7500 multi-mission aircraft. The platform will be equipped for government and military personnel...

TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today provided a project update with respect to the Purchase and Sale Agreement dated as of May 9, 2023, as amended pursuant to that First Amending Agreement, dated as of February 7, 2024 (the “Sheep Creek Stream”), among Carbon Streaming, Mast Reforestation SPV I, LLC (“Mast”) and its parent company DroneSeed Co., d/b/a Mast Reforestation (“Mast Parent Co”). Carbon Streaming has received a Notice of Adverse Impact from Mast and Mast Parent Co under the Sheep Creek Stream Agreement pursuant to which, among other things, Mast advised Carbon Streaming that the Sheep Creek project has experienced significantly higher than expected mortality rates and that the surviving seedlings had...